Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity
01:10am, Wednesday, 17'th Jul 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from two arms of an ongoing multi-part Phase
Dario Expands GLP-1 Solution Client Base with New Employer Contract
08:30am, Tuesday, 16'th Jul 2024
Dario's leading behavior change solutions continue to win interest in the employer, payer and pharmaceutical markets NEW YORK , July 16, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario"
Don't place your hopes on Hims & Hers GLP-1 business, says Jim Cramer
08:09pm, Wednesday, 10'th Jul 2024
'Mad Money' host Jim Cramer takes a look at Hims & Hers to assess if its a good healthcare move for your portfolio.
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
06:41am, Wednesday, 10'th Jul 2024
GLP-1 medicines for obesity are all the rage these days. Viking Therapeutics' candidate has the edge in the speed of weight loss.
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
09:10am, Tuesday, 09'th Jul 2024
All three dosing arms have been completed. KELOWNA, BC / ACCESSWIRE / July 9, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery pl
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
07:18am, Tuesday, 09'th Jul 2024
Global pharmaceutical company Eli Lilly & Co. NYSE: LLY has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been going heads-up against GLP-1 leader Novo Nordisk
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
10:39am, Monday, 01'st Jul 2024
Global pharmaceutical giant Eli Lilly & Co. NYSE: LLY has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is often used o
Hims & Hers shares plunge 12% amid allegations of GLP-1 drug sourcing from ‘shady supplier'
04:31am, Monday, 01'st Jul 2024
Roughly a month after announcing that it would offer GLP-1 injectable weight-loss drugs comparable to the popular drugs Ozempic and Mounjaro, Hims & Hers Health shares are taking a beating after a new
Hims & Hers shares fall on Hunterbrook report that GLP-1 drugs come from 'shady supplier'
06:13pm, Thursday, 27'th Jun 2024
Sam Koppelman, Hunterbrook Media publisher and co-founder, joins 'Closing Bell Overtime' to talk its report that Hims & Hers' GLP-1 offering is a 'knockoff' drug form 'shady supplier'.
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
03:35pm, Tuesday, 25'th Jun 2024
Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initia
Dario Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1
08:30am, Tuesday, 25'th Jun 2024
New research confirms behavior change driven by Dario digital platform is sustainable for 12 month period and supports clinical results for members taking a GLP-1 Additional research demonstrates 31%
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic dis
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
07:00am, Monday, 24'th Jun 2024
~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism w
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's 84th Scientific Sessions
01:30pm, Sunday, 23'rd Jun 2024
Single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model Rejuva also prevented weight and glycemic rebound after semaglutide
Zealand Pharma shares surge after positive results of weight-loss drug that could contend with GLP-1s
04:55am, Friday, 21'st Jun 2024
Shares of Zealand Pharma soared on Friday after the Danish biotech company reported positive results from a trial of its experimental weight-loss injection, that could compete with popular GLP-1s drug
